EP Patent

EP3863623A1 — Treatment of diseases associated with biliary system destruction

Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2021-08-18 · 5y expired

What this patent protects

The present invention relates to the field of neonatal cholestasis, in particular the treatment of neonatal biliary atresia or diseases associated with biliary system destruction. Also, the invention relates to methods and/or compounds for treating or preventing biliary atresia o…

USPTO Abstract

The present invention relates to the field of neonatal cholestasis, in particular the treatment of neonatal biliary atresia or diseases associated with biliary system destruction. Also, the invention relates to methods and/or compounds for treating or preventing biliary atresia or disease associated with biliary system destruction. It further relates to methods and/or compounds for slowing the progression of biliary atresia or disease associated with biliary system destruction.

Drugs covered by this patent

Patent Metadata

Patent number
EP3863623A1
Jurisdiction
EP
Classification
—
Expires
2021-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Centre National de la Recherche Scientifique CNRS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.